Evidence map›Paper›PMID 26114882›Full record

ArticlePLoS genetics2015

Abnormal Activation of BMP Signaling Causes Myopathy in Fbn2 Null Mice.

Gerhard Sengle, Valerie Carlberg, Sara F Tufa, Noe L Charbonneau, Silvia Smaldone, Eric J Carlson, Francesco Ramirez, Douglas R Keene, Lynn Y Sakai

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Missense variants ofMolecular genetics and metabolism reports · 2024
    Article
  5. Article
  6. Article
  7. Human MutatedInternational journal of molecular sciences · 2023
    Article
  8. Lack of evidence that fibrillin1 regulates bone morphogenetic protein 4 activity in kidney or lung.Developmental dynamics : an official publication of the American Association of Anatomists · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Identification of NovelFrontiers in genetics · 2022
    Article
  14. Article
  15. Article
  16. A new MMP-mediated prodomain cleavage mechanism to activate bone morphogenetic proteins from the extracellular matrix.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  17. Review
  18. Roles of Fibulin-2 in Carcinogenesis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Review
  19. A Novel Splicing Mutation in theFrontiers in genetics · 2020
    Article
  20. The "other" 15-40%: The Role of Non-Collagenous Extracellular Matrix Proteins and Minor Collagens in Tendon.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gerhard SengleDepartment of Biochemistry & Molecular Biology, Oregon Health & Science University, Portland, Oregon, United States of America; Shriners Hospital for Children, Portland, Oregon, United States of America.
Valerie CarlbergDepartment of Biochemistry & Molecular Biology, Oregon Health & Science University, Portland, Oregon, United States of America; Shriners Hospital for Children, Portland, Oregon, United States of America.
Sara F TufaShriners Hospital for Children, Portland, Oregon, United States of America.
Noe L CharbonneauShriners Hospital for Children, Portland, Oregon, United States of America.
Silvia SmaldoneDepartment of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America.
Eric J CarlsonShriners Hospital for Children, Portland, Oregon, United States of America.
Francesco RamirezDepartment of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, United States of America.
Douglas R KeeneShriners Hospital for Children, Portland, Oregon, United States of America.
Lynn Y SakaiDepartment of Biochemistry & Molecular Biology, Oregon Health & Science University, Portland, Oregon, United States of America; Shriners Hospital for Children, Portland, Oregon, United States of America.
Shriners Hospitals for Children - Portland · USIcahn School of Medicine at Mount Sinai · USOregon Health & Science University · US

Funding

PROJECT 4: Exploration of Therapeutic Strategies in MarP01AR049698 · NIAMS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI RAMIREZ, FRANCESCO B · 2004 to 2014
$13.9M
NIAMS NIH HHS P01 AR049698
6 · The paper itself

Abstract

Fibrillins are large extracellular macromolecules that polymerize to form the backbone structure of connective tissue microfibrils. Mutations in the gene for fibrillin-1 cause the Marfan syndrome, while mutations in the gene for fibrillin-2 cause Congenital Contractural Arachnodactyly. Both are autosomal dominant disorders, and both disorders affect musculoskeletal tissues. Here we show that Fbn2 null mice (on a 129/Sv background) are born with reduced muscle mass, abnormal muscle histology, and signs of activated BMP signaling in skeletal muscle. A delay in Myosin Heavy Chain 8, a perinatal myosin, was found in Fbn2 null forelimb muscle tissue, consistent with the notion that muscle defects underlie forelimb contractures in these mice. In addition, white fat accumulated in the forelimbs during the early postnatal period. Adult Fbn2 null mice are already known to demonstrate persistent muscle weakness. Here we measured elevated creatine kinase levels in adult Fbn2 null mice, indicating ongoing cycles of muscle injury. On a C57Bl/6 background, Fbn2 null mice showed severe defects in musculature, leading to neonatal death from respiratory failure. These new findings demonstrate that loss of fibrillin-2 results in phenotypes similar to those found in congenital muscular dystrophies and that FBN2 should be considered as a candidate gene for recessive congenital muscular dystrophy. Both in vivo and in vitro evidence associated muscle abnormalities and accumulation of white fat in Fbn2 null mice with abnormally activated BMP signaling. Genetic rescue of reduced muscle mass and accumulation of white fat in Fbn2 null mice was accomplished by deleting a single allele of Bmp7. In contrast to other reports that activated BMP signaling leads to muscle hypertrophy, our findings demonstrate the exquisite sensitivity of BMP signaling to the fibrillin-2 extracellular environment during early postnatal muscle development. New evidence presented here suggests that fibrillin-2 can sequester BMP complexes in a latent state.

Indexed as

AdipokinesAnimalsAnimals, NewbornBone Morphogenetic Protein 7Bone Morphogenetic ProteinsCreatine KinaseFemaleFibrillin-1Fibrillin-2FibrillinsGene Expression RegulationLimb Deformities, CongenitalMaleMice, Inbred C57BLMice, Mutant StrainsMicrofilament ProteinsAdipokinesbmp7 protein, mouseBone Morphogenetic Protein 7Bone Morphogenetic ProteinsCreatine KinaseFbn1 protein, mouseFbn2 protein, mouseFibrillin-1Fibrillin-2FibrillinsMicrofilament Proteins

Identifiers

PMID26114882
PMCPMC4482570
OpenAlexW795766042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.